«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2023 07

Page:

1344-1348

Research Field:

Publishing date:

Info

Title:

Research progress in the relationship between PD-1/PD-L1 and glioblastoma

Author(s):

WANG Gang; HAO Chuncheng

Harbin Medical University Cancer Hospital£¬Heilongjiang Harbin 150081£¬China.

Keywords:

glioblastoma£¨GBM£©; PD-1; PD-L1; immunotherapy

PACS:

R739.41

DOI:

10.3969/j.issn.1672-4992.2023.07.033

Abstract:

Glioblastoma (GBM) is the most aggressive and fatal primary brain tumor known.Despite extensive studies,the prognosis remains poor,with a median survival of only about 15 months.With the further recognition of the blood-brain barrier and the discovery of the close connection between the central nervous system and the deep cervical lymphatic system,GBM patients may benefit from the novel treatment mode of immunotherapy.PD-1/PD-L1 is the main target on the immune regulation axis,and the treatment mode for PD-1/PD-L1 has made breakthrough progress in various types of tumors,but it is still at the initial stage in research of GBM.This artical systematically describes the close relationship between PD-1/PD-L1 checkpoint and GBM,and summarizes the clinical progress of immunotherapy of PD-1/PD-L1 applied to GBM in recent years,so as to provide reference for clinical treatment.

References:

£Û1£ÝSTUPP R,MASON WP,VAN DEN BENT MJ,et al.Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma£ÛJ£Ý.N Engl J Med,2005,352(10):987-996.
£Û2£ÝSTUPP R,HEGI ME,MASON WP,et al.Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study:5-year analysis of the EORTC-NCIC trial£ÛJ£Ý.Lancet Oncol,2009,10(5):459-466.
£Û3£ÝMALLICK S,BENSON R,HAKIM A,et al.Management of glioblastoma after recurrence:A changing paradigm£ÛJ£Ý.J Egypt Natl Canc Inst,2016,28(4):199-210.
£Û4£ÝOSTROM QT,CIOFFI G,GITTLEMAN H,et al.CBTRUS statistical report:Primary brain and other central nervous system tumors diagnosed in the united states in 2012-2016£ÛJ£Ý.Neuro Oncol,2019,21(Suppl 5):v1-v100.
£Û5£ÝROSE AAN,ARMSTRONG SM,HOGG D,et al.Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy£ÛJ£Ý.J Immunother Cancer,2021,9(1):e001642.
£Û6£ÝCHEN D,MENON H,VERMA V,et al.Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer:retrospective analysis of two single-institution prospective trials£ÛJ£Ý.J Immunother Cancer,2020,8(1):e000492.
£Û7£ÝDONG H,STROME SE,SALOMAO DR,et al.Tumor-associated B7-H1 promotes T-cell apoptosis:a potential mechanism of immune evasion£ÛJ£Ý.Nat Med,2002,8(8):793-800.
£Û8£ÝASLAN K,TURCO V,BLOBNER J,et al.Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas£ÛJ£Ý.Nat Commun,2020,11(1):931.
£Û9£ÝPACHTER JS,DE VRIES HE,FABRY Z.The blood-brain barrier and its role in immune privilege in the central nervous system£ÛJ£Ý.J Neuropathol Exp Neurol,2003,62(6):593-604.
£Û10£ÝSUTER T,BIOLLAZ G,GATTO D,et al.The brain as an immune privileged site:Dendritic cells of the central nervous system inhibit T cell activation£ÛJ£Ý.Eur J Immunol,2003,33(11):2998-3006.
£Û11£ÝLOUVEAU A,HARRIS TH,KIPNIS J.Revisiting the mechanisms of CNS immune privilege£ÛJ£Ý.Trends Immunol,2015,36(10):569-577.
£Û12£ÝWOLBURG H,NOELL S,FALLIER-BECKER P,et al.The disturbed blood-brain barrier in human glioblastoma£ÛJ£Ý.Mol Aspects Med,2012,33(5-6):579-589.
£Û13£ÝJAIN S,CHALIF EJ,AGHI MK,et al.Interactions between anti-angiogenic therapy and immunotherapy in glioblastoma£ÛJ£Ý.Front Oncol,2022,11:812916.
£Û14£ÝWINTTERLE S,SCHREINER B,MITSDOERFFER M,et al.Expression of the B7-related molecule B7-H1 by glioma cells:a potential mechanism of immune paralysis£ÛJ£Ý.Cancer Res,2003,63(21):7462-7467.
£Û15£ÝANTONIOS JP,SOTO H,EVERSON RG,et al.Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma£ÛJ£Ý.Neuro Oncol,2017,19(6):796-807.
£Û16£ÝDONG Y,SUN Q,ZHANG X.PD-1 and its ligands are important immune checkpoints in cancer£ÛJ£Ý.Oncotarget,2017,8(2):2171-2186.
£Û17£ÝJAN CI,TSAI WC,HARN HJ,et al.Predictors of response to autologous dendritic cell therapy in glioblastoma multiforme£ÛJ£Ý.Front Immunol,2018,9:727.
£Û18£ÝDIDOMENICO J,LAMANO JB,OYON D,et al.The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma£ÛJ£Ý.Oncoimmunology,2018,7(7):e1448329.
£Û19£ÝLIU Y,CARLSSON R,AMBJ«ÁRN M,et al.PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients£ÛJ£Ý.J Neurosci,2013,33(35):14231-14245.
£Û20£ÝXUE S,SONG G,YU J.The prognostic significance of PD-L1 expression in patients with glioma:A meta-analysis£ÛJ£Ý.Sci Rep,2017,7(1):4231.
£Û21£ÝNDUOM EK,WEI J,YAGHI NK,et al.PD-L1 expression and prognostic impact in glioblastoma£ÛJ£Ý.Neuro Oncol,2016,18(2):195-205.
£Û22£ÝPRATT D,DOMINAH G,LOBEL G,et al.Programmed death ligand 1 is a negative prognostic marker in recurrent isocitrate dehydrogenase-wildtype glioblastoma£ÛJ£Ý.Neurosurgery,2019,85(2):280-289.
£Û23£ÝZENG J,ZHANG XK,CHEN HD,et al.Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas£ÛJ£Ý.Oncotarget,2016,7(8):8944-8955.
£Û24£ÝYU W,SHAO A,REN X,et al.Comparison of immune checkpoint molecules PD-1 and PD-L1 in paired primary and recurrent glioma:Increasing trend when recurrence£ÛJ£Ý.Brain Sci,2022,12(2):266.
£Û25£ÝMU L,LONG Y,YANG C,et al.The IDH1 mutation-induced oncometabolite,2-hydroxyglutarate,may affect DNA methylation and expression of PD-L1 in gliomasp£ÛJ£Ý.Front Mol Neurosci,2018,11:82.
£Û26£ÝTUMEH PC,HARVIEW CL,YEARLEY JH,et al.PD-1 blockade induces responses by inhibiting adaptive immune resistance£ÛJ£Ý.Nature,2014,515(7528):568-571.
£Û27£ÝLARKIN J,CHIARION-SILENI V,GONZALEZ R,et al.Combined nivolumab and ipilimumab or monotherapy in untreated melanoma£ÛJ£Ý.N Engl J Med,2015,373(1):23-34.
£Û28£ÝREARDON DA,BRANDES AA,OMURO A,et al.Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma:The CheckMate 143 phase 3 randomized clinical trial£ÛJ£Ý.JAMA Oncol,2020,6(7):1003-1010.
£Û29£ÝCHAMBERLAIN MC,KIM BT.Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab:a retrospective case series£ÛJ£Ý.J Neurooncol,2017,133(3):561-569.
£Û30£ÝREISS SN,YERRAM P,MODELEVSKY L,et al.Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas£ÛJ£Ý.J Immunother Cancer,2017,5(1):99.
£Û31£ÝDE GROOT J,PENAS-PRADO M,ALFARO-MUNOZ K,et al.Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages£ÛJ£Ý.Neuro Oncol,2020,22(4):539-549.
£Û32£ÝCLOUGHESY TF,MOCHIZUKI AY,ORPILLA JR,et al.Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma£ÛJ£Ý.Nat Med,2019,25(3):477-486.
£Û33£ÝANTONIA SJ,VILLEGAS A,DANIEL D,et al.Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer£ÛJ£Ý.N Engl J Med,2017,377(20):1919-1929.
£Û34£ÝCACCESE M,INDRACCOLO S,ZAGONEL V,et al.PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma:A concise review£ÛJ£Ý.Crit Rev Oncol Hematol,2019,135:128-134.
£Û35£ÝLUKAS RV,RODON J,BECKER K,et al.Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma£ÛJ£Ý.J Neurooncol,2018,140(2):317-328.
£Û36£ÝOZPISKIN OM,ZHANG L,LI JJ.Immune targets in the tumor microenvironment treated by radiotherapy£ÛJ£Ý.Theranostics,2019,9(5):1215-1231.
£Û37£ÝZENG J,SEE AP,PHALLEN J,et al.Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas£ÛJ£Ý.Int J Radiat Oncol Biol Phys,2013,86(2):343-349.
£Û38£ÝREARDON DA,GOKHALE PC,KLEIN SR,et al.Glioblastoma eradication following immune checkpoint blockade in an Orthotopic,Immunocompetent Model£ÛJ£Ý.Cancer Immunol Res,2016,4(2):124-135.
£Û39£ÝWAINWRIGHT DA,CHANG AL,DEY M,et al.Durable therapeutic efficacy utilizing combinatorial blockade against IDO,CTLA-4,and PD-L1 in mice with brain tumors£ÛJ£Ý.Clin Cancer Res,2014,20(20):5290-5301.
£Û40£ÝMEDIKONDA R,CHOI J,PANT A,et al.Synergy between glutamate modulation and anti-programmed cell death protein 1 immunotherapy for glioblastoma£ÛJ£Ý.J Neurosurg,2022,136(2):379-388.

Memo

Memo:

-

Common functions

Last Update: 2023-02-28